Clinically significant borderline resistance of sequential clinical isolates of Klebsiella pneumoniae

International Journal of Antimicrobial Agents

Volumn 22, Issue 4, 2003, Pages 367-373

  Wagenlehner, F M E ^a,c   Heisig, P ^b   Irtenkauf, C ^a   Notka, F ^a   Decker, J ^a   Lehn, N ^a   Linde, H ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c Urologische Klinik   (Germany)

Author keywords

Clinical aspects; Efflux; Fluoroquinolone resistance; Klebsiella pneumoniae

Indexed keywords

AGAR; CIPROFLOXACIN; DNA TOPOISOMERASE; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM MUTANT; BIOACCUMULATION; CASE REPORT; CONTROLLED STUDY; CULTURE MEDIUM; EFFUSION; GENETIC ANALYSIS; HUMAN; IMMUNE DEFICIENCY; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; LUNG LAVAGE; MINIMUM INHIBITORY CONCENTRATION; PNEUMONIA; PRIORITY JOURNAL; SPUTUM; WEGENER GRANULOMATOSIS; WILD TYPE;

EID: 0141680708     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00126-2     Document Type: Article

References (24)

1. Kern W.V., Oethinger M., Jellen-Ritter A.S., Levy S.B. Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 44:2000;814-820.
2. Linde H.J., Notka F., Metz M., Kochanowski B., Heisig P., Lehn N. In vivo increase in resistance to ciprofloxacin in Escherichia coli associated with deletion of the C-terminal part of MarR. Antimicrob. Agents Chemother. 44:2000;1865-1868.
3. National Committee for Clinical Laboratory Standards (NCCLS). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, M7-A4, 4th ed. Wayne, PA: National Committee for Clinical Laboratory Standards. 1997.
4. Hüllen V, Heisig P, Wiedemann B. Abstract 37th Interscience Conference on Antimicrobial Agents Chemotherapy, abstract C-64; 1997. p. 57.
5. Gautom R.K. Rapid pulsed-field gel electrophoresis protocol for typing of Escherichia coli O157:H7 and other gram-negative organisms in 1 day. J. Clin. Microbiol. 35:1997;2977-2980.
6. Martinez-Martinez L., Garcia I., Ballesta S., Benedi V.J., Hernandez-Alles S., Pascual A. Energy-dependent accumulation of fluoroquinolones in quinolone-resistant Klebsiella pneumoniae strains. Antimicrob. Agents Chemother. 42:1998;1850-1852. published erratum appears in Antimicrob Agents Chemother 1998 October; 42 (10):2772.
7. Maniatis T., Fritsch E.F., Sambrook J. Molecular cloning: a laboratory manual. 1982;Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
8. Sambrook J., Fritsch E.F., Maniatis T. Molecular cloning: a laboratory manual. 2nd ed:1989;Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
9. Knopf H.J., Schlenkhoff D., Opferkuch W., Dalhoff A. Pharmakokinetische Untersuchungen zum Konzentrationsverhalten von Ciprofloxacin in Lungenparenchym Serum und Urin nach einer einmaligen i.v. Gabe. Fortschritte der Antimikrobiellen und antineoplastischen Chemotherapie. 6:(3):1987;507-511.
10. Andes D., Craig W.A. Animal model pharmcokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents. 19:(4):2002;262-268.
11. Bender S.W., Dalhoff A., Shah P.M., Strehl R., Posslet H.G. Ciprofloxacin pharmacokinetics in patients with cystic fibrosis. Infection. 14:(1):1986;17-21.
12. Threlfall E.J., Ward L.R., Skinner J.A., Smith H.R., Lacey S. Ciprofloxacin-resistant Salmonella typhi and treatment failure. Lancet. 353:1999;1590-1591.
13. Shah P.M. Zur Resistenz von Salmonella Typhi gegenüber Chinolonen. Epidemiologisches Bull. 25:2002;207.
14. Takashi Deguchi, Akihisha Fukuoka, Mitsuru Yasuda, et al. Alterations in the GyrA subunit of DNA Gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother. 1997;41:699-701.
15. Weigel L.M., Steward C.D., Tenover F.C. gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob. Agents Chemother. 42:1998;2661-2667.
16. Aono R. Improvement of organic solvent tolerance level of Escherichia coli by overexpression of stress-responsive genes. Extremophiles. 2:1998;239-248.
17. Cohen S.P., Hächler H., Levy S.B. Genetic and functional analysis of the multiple antibiotic resistance (mar) locus in Escherichia coli. J. Bacteriol. 175:1993;1484-1492.
18. Haruko O., Dzwokai M., Hiroshi N. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. J. Bacteriol. 178:1996;306-308.
19. Miller P.F., Sulavik M.C. Overlaps and parallels in the regulation of intrinsic multiple-antibiotic resistance in Escherichia coli. Mol. Microbiol. 21:1996;441-448.
20. Oethinger M., Podglajen I., Kern W.V., Levy S.B. Over expression of the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia coli. Antimicrob. Agents Chemother. 42:1998;2089-2094.
21. Domenech-Sanchez A, Alberti S, Martinez-Martinez L, Pascual A, Garcia I, Benedi VJ. Genetic characterization and role in antimicrobial resistance of the AcrAB efflux pump of Klebsiella pneumoniae. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2001, C1-2018.
22. Jellen-Ritter A.S., Kern W.V. Enhanced expression of the multidrug efflux pumps AcrAB and AcrEF associated with insertion element transposition in Escherichia coli mutants selected with a fluoroquinolone. Antimicrob. Agents Chemother. 45:2001;1467-1472.
23. Everett M.J., Jin Y.F., Ricci V., Piddock L.J. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob. Agents Chemother. 40:1996;2380-2386.
24. Tran J.H., Jacoby G.A. Mechanism of plasmid-mediated quinolone resistance. Proc. Natl. Acad. Sci. USA. 99:2002;5638-5642.